1.75Open1.70Pre Close42 Volume216 Open Interest10.00Strike Price7.33KTurnover239.52%IV18.66%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry1.50Extrinsic Value100Contract SizeAmericanOptions Type-0.3720Delta0.0802Gamma6.53Leverage Ratio-0.0696Theta-0.0018Rho-2.43Eff Leverage0.0074Vega
Alto Neuroscience Stock Discussion
Core business and technology:
Personalized Medication: Alto Neuroscience’s goa...
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
No comment yet